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1. Introduction 
Among all biomolecules in living cells, proteins represent a group with highly divergent 
biological functions. These include maintaining structural integrity, catalyzing most 
chemical reactions in vivo, regulating cellular responses via signal transduction, and 
targeting foreign molecules via the immune system. Because of these diverse functions and 
associated applications, protein engineering has been a field for intense academic research 
and biopharmaceutical drug development. However, proteins made by nature are generally 
composed of only 20 canonical amino acids. The recently developed technology to 
incorporate non-natural amino acids (NNAAs) into proteins at specifically chosen sites 
represents an extremely powerful tool for protein engineering. Unlike traditional protein 
engineering with the 20 canonical amino acids as building blocks, protein engineering with 
NNAAs has nearly unlimited novel side-chain structures to choose from. Coupled with 
rapid advances in protein structure computation and bioorthogonal chemical reactions, 
proteins with tailored properties or novel functions beyond natural or directed evolution are 
becoming a reality. 
In this book chapter, we will first review technologies being developed to incorporate 
NNAAs into proteins. While NNAAs can be incorporated via chemical synthesis, or in vitro 
cell-free protein translation systems, we will focus our review on cell-based protein 
expression systems because of their capacity for large scale manufacturing. Examples of 
different ways to assign genetic codons for NNAAs will be reviewed and compared with 
each other in terms of incorporation efficiency at desired site(s), sequence fidelity of the 
engineered protein, protein yield, and scalability. Then we will provide examples of 
chemical conjugation reactions that are orthogonal to the naturally occurring functional 
groups present in proteins. Topics include reaction kinetics, effect of the reaction conditions 
on protein, and stability of the final conjugate. At the end, we will highlight a few potential 
applications of proteins engineered with NNAAs. A special focus will be on therapeutic 
proteins for clinical use. It is our hope that with this review, more scientists in the protein 
engineering field will harness this powerful technology and apply it to meet the challenges 
in their work. 
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2. Methodologies for incorporating non-natural amino acids into proteins 
Protein translation is the process where the genetic information, stored as triplet codon 
sequence in the mRNA, is used to dictate the polypeptide synthesis. The components required 
in protein translation were first postulated in the original Adaptor hypothesis by Crick in 1958, 
and were subsequently identified experimentally (Ibba et al., 2000). During the course of 
protein synthesis, a ribosome moves along an mRNA molecule and pairs each triplet codon 
with the adaptor aminoacyl-tRNA containing the complementary anticodon, and catalyzes the 
formation of a peptide bond with the growing polypeptide chain (Figure 1). 
 
Fig. 1. Natural protein translation system. Aminoacyl-tRNA synthetases (aaRSs) play a key 
role in maintaining the fidelity of protein translation by demonstrating strict specificity for 
their cognate amino acid and their tRNA. (1) Each aaRS recognizes unique structural 
elements of its cognate tRNA(s) and amino acid. (2) The aaRS joins the amino acid to the 
tRNA, forming the aminoacyl-tRNA (3) that is released into the cytosol. (4) As the ribosome 
moves along an mRNA molecule, codons are paired with aminoacylated tRNAs containing 
the complementary anticodons. The ribosome catalyses the sequential peptide-bond 
formation of amino acids delivered by tRNAs, generating the nascent protein. At the end of 
translation, release factors occupy stop codons and trigger the termination of protein 
synthesis. (5) Deaminoacylated tRNA is recycled for further use. 
Translation is a highly regulated process, and protein sequence fidelity is largely controlled 
at two steps: 1) the correct coupling of the amino acid with the tRNA to generate the 
aminoacyl-tRNA; 2) the correct pairing of the anticodon in the aminoacyl-tRNA with the 
codon in mRNA. The former is governed by the function of the aminoacyl-tRNA 
synthetases (aaRSs). The substrate selectivity for tRNA is accomplished through structural 
recognition elements that are unique to each tRNA and often include the anticodon site. The 
substrate specificity for the amino acid is achieved by a highly selective amino acid binding 
pocket. Some aaRSs cannot distinguish between structurally similar amino acids, but they 
have evolved an editing function to eliminate mis-acylated tRNAs. In most cells, there are 20 
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aaRS enzymes, one for each amino acid. The 20 canonical amino acids are encoded by 61 
codons, with most amino acids encoded by more than one codon. Protein translation is 
terminated at one of the three stop codons by the protein release factors (RF). It should be 
mentioned that there are exceptions to nearly every rule in the general description of the 
translation process. These exceptions actually provide some of the tools that protein 
engineers have used to introduce NNAAs into proteins, and will be described in subsequent 
sections. 
Several methods have been developed for genetically encoding NNAAs into recombinant 
proteins. These methodologies range from simple exploitation of the promiscuity of the 
endogenous protein translation system in the host cells, to the introduction of an exogenous 
aaRS/tRNA pair specifically designed for a NNAA. All these methods manipulate the 
natural protein translation process and rely on the reassignment of a genetic codon (such as 
a sense codon or a stop codon) to the NNAA of interest. As a result, incorporation of the 
NNAA is intrinsically in competition with certain natural processes: for example, 
competition from the natural amino acid for a sense codon, or from the release factor for a 
stop codon. This competition impacts on the efficiency of NNAA incorporation, sequence 
fidelity as well as the expression yield of target proteins. The ability to reduce or totally 
eliminate such competition will significantly expedite protein engineering with NNAAs. 
Recent progress in synthetic biology, which enables the generation of artificial cells with 
synthetic genomes, shows great promise for such a goal. In this section, we will first 
describe methods to evolve aaRSs and tRNAs for NNAAs, and then review NNAA 
incorporation methods based on codon reassignment. 
2.1 Methods for evolution of aaRSs and tRNAs for NNAAs 
Site-specific introduction of NNAAs requires the expression of an aaRS/tRNA pair specific to 
a NNAA in the expression host. While this pair must integrate seamlessly with the host 
translational apparatus, controlled insertion of NNAAs at desired sites requires that it be 
orthogonal to the host cell. That is, the aaRS/tRNA pair should have the following properties: 
the introduced aaRS should aminoacylate only NNAA to its cognate tRNA, but not any of the 
host tRNAs. This avoids mis-incorporation of the NNAA at other codons; in turn, the 
introduced tRNA should be activated only by its cognate aaRS, but not any of the host aaRSs. 
This ensures that only the NNAA is incorporated at its assigned codon. The orthogonality of 
the aaRS/tRNA pair within the expression host cell is essential to maintain sequence fidelity of 
the target proteins. By exploiting the evolutionary divergence between species, orthogonal 
aaRS/tRNA pairs have been obtained by transferring an aaRS/tRNA pair from one species 
into another. An alternate approach requires the re-engineering of recognition elements of the 
aaRS and its tRNA de novo to achieve orthogonality (Neumann et al., 2010a). 
While most cells contain 20 aaRSs, some species have evolved additional aaRSs to allow for 
the utilization of other naturally occurring, but non-canonical amino acids. Pyrrolysine (Pyl) 
is used by several species of the methanogenic archea, Methanosarcina. In its native context, 
the PylRS/tRNA evolved alongside the 20 canonical aaRSs and developed natural 
specificity for its cognate amino acid, making it an ideal pair for transfer into other 
expression hosts. Indeed, the PylRS/tRNA has been shown to be fully orthogonal in E. coli, 
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yeast and mammalian cells (reviewed by Voloshchuk & Montclare, 2010). Furthermore, Pyl 
is naturally encoded by the amber stop codon, the most commonly reassigned codon to 
specify a NNAA, and thus requires no engineering to adapt it to this purpose. However, the 
Pyl-tRNA is not hardwired for amber codon suppression, and can be adapted to decode a 
number of other codons (Ambrogelly et al., 2007). In addition, the PylRS has been shown to 
readily accept a variety of side chain structures (Polycarpo et al., 2006;Yanagisawa et al., 
2008;Neumann et al., 2008;Chen et al., 2009;Nguyen et al., 2009;Li et al., 2009;Hancock et al., 
2010;Ou et al., 2011;Plass et al., 2011;Takimoto et al., 2011) as well as a set of non-alpha amino 
derivatives (Kobayashi et al., 2009). This feature makes the PylRS/tRNA pair an ideal 
candidate for site specific integration of NNAAs. 
2.1.1 Positive/negative selection  
Alternating positive and negative screens were pioneered by Schultz’s group to evolve 
orthogonal aaRS/tRNA pairs from large mutational libraries for NNAA incorporation at a 
stop codon (reviewed by Liu & Schultz, 2010). Figure 2 illustrates the application for 
evolving aaRSs: First, an aaRS mutant library, along with its cognate tRNA and a 
conditionally required gene, whose open reading frame is interrupted by a stop codon, is 
introduced to the host cells for positive selection. Cells are grown the presence of NNAA 
and only cells with a functional aaRS/tRNA pair (for either NNAA or canonical amino 
acids) will enable the expression of the essential gene for survival. The selected aaRS 
mutants (along with the suppressor tRNA) are then shuffled into the host containing a toxic 
gene (containing an in frame stop codon) for negative selection. When cells are grown in the 
absence of NNAA, cells containing the aaRS variants that activate canonical amino acids 
will express the full-length lethal protein and be eliminated; cells containing aaRSs that 
activate NNAA but not canonical amino acids will survive. The resulting aaRS mutants will 
be shuffled back for multiple iterations of positive and negative selections until the library 
converges and/or the desired functionality of the aaRS is obtained. While the alternating 
positive and negative screen has proven to be extremely successful, the strategy requires 
plasmid shuttling that is time consuming and affects library diversity. In addition, the 
common practice of using antibiotic resistance genes for positive selection, while effective, 
can lead to unexpected variability of identified mutants (Pastrnak & Schultz, 2001;Young et 
al., 2010). Furthermore, this scheme does not eliminate the mis-acylation of host tRNA(s) 
with the NNAA by some aaRS variants, leading to potential non-orthogonality of the 
aaRS/tRNA pair and the introduction of NNAA at undesired sites.  
The positive/negative selection (or its various modified formats) is the most widely 
practiced method for evolving orthogonal aaRS/tRNA pairs. While it was initially 
developed for an E. coli expression system, its principle has been applied successfully in 
yeast (Chin et al., 2003). Development of orthogonal aaRS/tRNA pairs for mammalian 
expression faces some additional challenges. Due to the low efficiency of mammalian cell 
transfection and their relatively slow growth, it is impractical to screen large libraries and 
evolve aaRSs directly in mammalian cells. Instead, aaRS/tRNA pairs derived from 
prokaryotes and developed for yeast hosts have been adapted successfully for mammalian 
expression. For example, both the E. coli TyrRS/tRNA pair and E. coli TyrRS paired with 
Bacillus stearothermophilus (B.St) tRNA were successfully transferred to mammalian cells (Liu 
et al., 2007;Wang et al., 2007b;Takimoto et al., 2009) 
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Fig. 2. An alternating positive and negative screen for evolving orthogonal aaRSs and 
tRNAs. (1) A library of aaRS mutants and its cognate tRNACUA are introduced into an 
expression host containing a conditionally essential gene (e.g. antibiotic resistance marker) 
with an amber stop codon interrupting its open reading frame and grown in medium 
containing NNAA. (2) Cells containing functional aaRSs express the full-length essential 
gene and are able to survive under selective conditions (e.g., presence of antibiotic). (3) 
Surviving cells are harvested and the aaRS/tRNACUA variants are introduced into cells 
containing a gene (with an amber codon) that when expressed is lethal (e.g. Barnase), and 
grown in the absence of NNAA. (4) Cells containing orthogonal NNAA aaRS/tRNACUA 
pairs express truncated non-functional Barnase and get selected for the next round of 
screening. 
2.1.2 Green fluorescent protein (GFP)-based selection 
A more streamline scheme utilizing GFP for both positive and negative selection was 
developed to evolve aaRS/tRNA pair in E. coli (Santoro et al., 2002). The method depends on 
antibiotic resistance and the expression of GFP, and enables high throughput screening of 
library variants by FACS. A single plasmid carrying two reporter genes, the 
chloramphenicol resistance gene containing an amber codon, and a GFP gene that depends 
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on amber suppression for its expression, was used to select Methanococcus jannaschii (Mj.) 
TyrRS mutants in the presence of its cognate tRNACUA. Positive selection was performed in 
medium containing chloramphenicol and a NNAA, and the isolation of live green bacteria 
led to bacteria cells carrying functional Mj. TyrRS. Negative selection was performed in 
medium lacking both the antibiotic and the NNAA. By isolating non-fluorescent cells, Mj. 
TyrRS mutants that incorporated natural amino acids were eliminated. The resulting clones 
were then retested for growth on chloramphenicol in the presence of the NNAA. This screen 
led to the identification of mutations that preferred p-isopropyl-Phe, p-amino-Phe, and O-
allyl-Tyr (Santoro et al., 2002). 
2.1.3 Surface-display-based selection 
Phage (or yeast, or any cell surface) display utilizes the special properties of NNAA-
containing peptides displayed on the cell surface for screening and selection of functional 
aaRSs (or tRNAs) from a vast number of variants in a library. NNAAs with special binding 
properties to a particular type of immobilized resin or ligand may be used for selection. For 
example, proteins containing a boronate amino acid, which forms strong and reversible 
complexes with polyols and cis-diols, could be selected on N-methylglucamine resin 
(Brustad et al., 2008). Alternatively, a monoclonal antibody that binds specifically to a 
NNAA-containing peptide may be used for selection (Pastrnak & Schultz, 2001); conjugation 
of a florescent tag to the NNAA (containing a special chemical reactive group) displayed on 
the cell surface, followed by cell sorting via flow cytometry, may also lead to selection of the 
aaRS or tRNA. In fact, MetRS mutants with improved activities toward azidonorleucine and 
better discrimination against Met were generated via surface labelling and cell sorting 
(Tanrikulu et al., 2009). The surface-display based selection can be applied to evolve 
aaRS/tRNA for either a sense codon or a stop codon. The limitation of the method is that the 
method may not be readily applicable to any NNAA, as it relies on the special properties of 
the NNAA or on antibody reagents. 
2.1.4 Rational design for selection 
Rational design predicts structural changes needed for NNAA activation based on a solved 
(or simulated) aaRS structure for its cognate amino acid. By computationally simulating the 
binding (or editing) sites and binding energy for a NNAA, putative mutations that favour 
the introduction of a NNAA over the natural amino acid can be identified and tested 
experimentally. This approach avoids the laborious generation and screening of a large aaRS 
mutation library, and is expected to be utilized more frequently as structural prediction 
algorithms improve. An example of this approach was the successful development of an 
orthogonal yeast PheRS/tRNA pair for the incorporation of a NNAA at an amber stop 
codon in E coli.  By sequence and structural analysis of PheRS from various species, a key 
residue in yeast PheRS (T415) was identified that could relax the specificity of the amino 
acid binding pocket and allow for the incorporation of NNAAs (Kwon et al., 2006). In 
combination with a yeast amber suppressor Phe-tRNACUA-UG (which was designed to limit the 
cross-reactivity of the tRNA with the E. coli LysRS), the mutant PheRS (T415G or A) enabled 
the incorporation of several Trp or Phe analogs in a site specific manner, with greater than 98% 
NNAA occupancy at the amber site (Kwon et al., 2006;Kwon & Tirrell, 2007).  
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Similarly, rational design on tRNA can lead to a smaller number of candidates for the 
generation of orthogonal tRNAs. For example, the amber suppressor Trp-tRNACUA from 
yeast was found to be mis-acylated by endogenous LysRS in E. coli (Hughes & Ellington, 
2010). Analysis of the tRNA structure revealed that the yeast amber suppressor Trp-
tRNACUA shares 73% sequence homology with E. coli Lys-tRNAUUU, and contains several 
key identity elements for the recognition of E. coli Lys-tRNAUUU by its cognate aaRS. 
Furthermore, structural analysis revealed that the modification of the G:C content of the 
anticodon stem may reduce the structural flexibility of this stem and eliminate mis-
acylation. Combined with experimental testing, an orthogonal and functional yeast Trp-
tRNACUA was obtained for the incorporation of NNAAs (Hughes & Ellington, 2010). 
2.2 Methods for incorporation of NNAAs into recombinant proteins 
2.2.1 Reassigned sense codon 
The simplest method to introduce NNAAs into proteins exploits the promiscuity of aaRSs of 
the host cells. That is, when a particular aaRS can charge a NNAA non-specifically to its 
cognate tRNA, the activated NNAA-tRNA may be utilized by the ribosomal translation 
machinery, and the NNAA added to the nascent polypeptide chain according to the sense 
codon specified for the canonical amino acid. The sense codon is reassigned to the NNAA, 
resulting in a recombinant protein composed of 19 canonical amino acids and one NNAA. 
Thus, this is a residue-specific global substitution method. 
The successful substitution of a canonical amino acid with a NNAA relies on the use of 
auxotrophic expression hosts deficient in the biosynthesis of that amino acid. Employment 
of such hosts limits competition from the canonical amino acid for the reassigned sense 
codon, and improves the incorporation efficiency and yield of target proteins. For example, 
the MetRS has a relatively relaxed substrate binding pocket, and a number of Met analogs 
have been successfully incorporated into target proteins (reviewed by Hendrickson et al., 
2004;Voloshchuk & Montclare, 2010). A special consideration worth mentioning when using 
Met analogs for protein engineering is the in vivo processing of NNAAs at the N-terminus of 
proteins. It is well know that most protein translation starts with a Met codon, and that Met 
at the N-terminus of proteins is subjected to enzyme-mediated processing, resulting either 
in the retention or cleavage of N-terminal Met. The rule for such N-terminal processing 
depends on the identity of the 2nd amino acid in the protein sequence. A set of similar but 
not identical rules have been established for the N-terminal processing of NNAAs in 
recombinant interferon (Wang et al., 2008) as well as other proteins (unpublished data). As a 
result, the N-terminal NNAA can be either retained or cleaved by choosing an appropriate 
2nd residue (Table 1). 
2nd residual Aha cleavage% Hpg cleavage%
Ala 96 91
Ser 80 80
Gly 52 33
Gln 8 0
Glu 0 0
His 0 0
Table 1. N-terminal processing of Met analog Aha or Hpg (structures provided in Fig 4) 
in E. coli.  
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Besides the Met codon, many other sense codons (such as codons for Pro, Tyr, Phe, Leu, Val 
etc.) have also been reassigned, and more than 60 NNAAs have been incorporated into 
proteins via global substitution (reviewed by Hendrickson et al., 2004;Voloshchuk & 
Montclare, 2010). In many cases, the intracellular level of wild-type aaRS may need to be 
augmented in order to compensate for the low activity of native aaRS towards the NNAA. In 
other cases, engineered aaRSs with higher catalytic activity towards the NNAA could be 
supplied to the expression host cells. An impressive example is with a MetRS mutant, which 
was identified via cell-surface display. The mutant MetRS activated azidonorleucine two-fold 
more efficiently than Met. As a result, the target protein was expressed with azidonorleucine 
at higher levels than with Met (Tanrikulu et al., 2009). By utilizing auxotrophic host cells for 
two or more canonical amino acids, it may be possible to produce recombinant proteins with 
more than one type of NNAA by this strategy. Furthermore, the global substitution method 
may be applied in other expression hosts, such as mammalian cells. 
It should be mentioned that while native or mutant aaRSs can utilize NNAAs to replace a 
canonical amino acid in vivo, most NNAAs don’t support the normal growth and expansion 
of host cells, presumably due to the impairment of some protein functions when a NNAA is 
incorporated. As a result, cell density (and thus protein expression yield) is affected during 
the induction phase when a NNAA is added into the media. Adaption of host strains to the 
NNAA may provide a solution. By gradually increasing the amount of NNAA in the growth 
media until complete replacement was accomplished, E. coli hosts capable of surviving in 
media containing 4-fluoro-Trp were evolved (Bacher & Ellington, 2001). These evolved E. 
coli hosts contain 3 mutant enzymes involved in the uptake and utilization of Trp, and are 
capable of fully substituting 4-fluoro-Trp in their proteomes. Utilization of such adapted 
expression hosts represents another approach to improve the yield and NNAA 
incorporation efficiency.  
The main limitation of this technology is that the NNAA will replace the canonical amino acid 
throughout the protein sequence, which may restrict its application if such global substitution 
is undesired. One solution to this problem is to mutate undesired sites with other canonical 
amino acids so that the desired site(s) is reserved for NNAA. To this end, functional target 
proteins lacking a particular amino acid have been generated, such as Met-free human 
interferon beta or scFv (unpublished data) and Phe-free GFP (Goltermann et al., 2010). With 
these proteins, the NNAA can be site-specifically incorporated at any desired site. 
Alternatively, site-specific incorporation can be accomplished via the introduction of an 
aaRS/tRNA pair specifically designed for the NNAA, as described in the following sections. 
The global substitution technology offers many advantages, which include: 1) the efficiency 
of NNAA incorporation, which can be near 100% at lab scale using a media exchange 
procedure. At production scale with a media depletion procedure, the incorporation 
efficiency can still reach 85-90% (unpublished data); 2) the target protein sequence is tightly 
controlled. In general, the NNAA incorporates only at the reassigned sense codon; the 
protein sequence at all other codons is strictly controlled and not affected by the reassigned 
sense codon; 3) target protein expression level is generally very high, even for proteins 
containing multiple copies of the NNAA. Protein yields at 10-100mg/L have been reported 
(Link & Tirrell, 2005) in shaker flasks, and yields of up to several gram/L can be achieved 
via high-density fermentation in bioreactors (unpublished data); 4) the expression system is 
simple and well-controlled, and the fermentation process is highly scalable. Thus, this 
technology is amendable for large-scale manufacture. 
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2.2.2 Wobble codon 
Wobble codons refer to codons that are decoded by tRNA via non-classical Watson-Crick 
base-pairing. As there are 61 sense codons to encode 20 canonical amino acids, but fewer 
than 50 tRNAs in many organisms (Sharp et al., 2005) (for a tRNA database on different 
organisms: http://gtrnadb.ucsc.edu/), some tRNA must pair with more than one codon. 
The non-classical (or wobble) pairing is enabled through modification at the tRNA’s 1st 
anticodon base (which pairs with the 3rd base to the codon triplet), as proposed in the 
“Wobble Hypothesis”(Crick, 1966). For example, many organisms have only one Phe-
tRNAGAA to decode two codons for Phe: UUU and UUC. As a result, the GAA anticodon 
binds to the UUC codon via Watson-Crick base-pairing, and to the UUU codon via 
“wobble” base-pairing.  While many more modifications on tRNA have since been 
identified over the last 40 years, and the “Wobble Hypothesis” has been modified and 
expanded, the essential premise remains the same: through various base modifications, the 
anticodon structure is shaped in a way that enables it to bind to cognate and wobble bases at 
the ribosome (Agris et al., 2007). 
Because of the wobble pairing between codon and anticodon, one tRNA may pair with 
several codons, and a given codon may pair with more than one tRNAs. However, pairing 
at a wobble codon may be less effective to support protein translation (Curran & Yarus, 
1989;Sharp et al., 2005). Taking advantage of this property, a wobble codon may be assigned 
to a NNAA to generate recombinant protein that contains 20 canonical amino acids and one 
NNAA, as described below. 
 
 
Fig. 3. Site-specific integration of NNAAs at wobble codons. Phe is normally encoded by 
two codons UUC and UUU, with both codons recognized by the tRNAGAA. By expressing an 
orthogonal aaRS/tRNAAAA (O-RS and O-tRNA) pair, with specificity for a NNAA and 
containing the “AAA” anticodon, efficient introduction of the NNAA at UUU codons can be 
achieved.  
To assign a wobble codon to a NNAA, a heterologous PheRS/tRNAAAA pair from the yeast 
S. cerevisiae was introduced into an E. coli Phe auxotrophic expression host containing the 
target gene under a strong inducible promoter (Kwon et al., 2003). In this system, the yeast 
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PheRS was engineered to activate 2-naphthylalanine to the yeast Phe-tRNAAAA, and the 
target gene was designed with a UUC codon for all desired Phe sites, and a UUU wobble 
codon was reserved at specific sites for 2-naphthylalanine (Figure 3). 
With this method, Phe can be essentially quantitatively assigned to the UUC codon, and 
NNAA to the UUU wobble codon at approximately 80% efficiency in E. coli expression host 
(Link & Tirrell, 2005). Furthermore, multiple copies of a NNAA can be introduced site-
specifically into a target protein. The expression level of target protein, however, is typically 
an order of magnitude lower than the global sense codon reassignment method, on the 
order of 2-5 mg DHFR per liter with shaker flasks. The applicability of this method in other 
expression hosts such as yeast and mammalian cells remains to be investigated.  
2.2.3 Bias codon 
It is well known that degenerate codons are not used with equal frequency in many 
organisms. The preferred codons are the ones that match the tRNAs that are most abundant 
in the cells, and this codon preference is more evident in rapidly multiplying organisms or 
in highly expressed genes. Presumably, codon usage and tRNA gene content coevolved to 
match each other, and in doing so, organisms effectively minimize the energy and time costs 
for protein translation and cell growth (Higgs & Ran, 2008).  
The preferred codons differ between organisms, and even between different tissues or cell 
types of the same organism. The cellular content of tRNA species is a determining factor on 
the rates and amounts of protein synthesized (Gu et al., 2004). As a consequence, 
recombinant protein production in heterologous host cells is often codon-optimized to 
match the preferred host cell codon bias (The codon usage database for different organisms 
and codon analysis of a given gene can be found at: http://www.kazusa.or.jp/codon/). 
The biased codon usage provides another method to introduce NNAAs into recombinant 
proteins. For example, out of the six degenerate codons for Arg, AGG and AGA are rarely 
used in E. coli. Introduction of an orthogonal ArgRS/tRNACCU pair into an E. coli expression 
host may enable the NNAA-activated orthogonal tRNACCU to compete effectively with the 
low endogenous E. coli Arg-tRNACCU. This method has been proven feasible with an in vitro 
cell-free based system, where chemically synthesized NNAA-tRNACCU was incorporated at 
AGG codons (Hohsaka et al., 1994). The method could be adapted to E. coli cell-based 
expression system if orthogonal ArgRS/tRNA pair can be engineered. 
Similarly, a bias codon may be assigned to a NNAA in mammalian cells that exhibit codon 
bias. For example, through study of human papillomavirus gene expression in different 
mammalian cells, Frazer and his colleagues have found that papillomavirus protein 
expression is determined by the codon usage and tRNA availability. Substantial differences 
in the tRNA pools were discovered between differentiated and undifferentiated 
keratinocytes (Zhao et al., 2005), and the observed bias in their tRNA may be the reason that 
papillomavirus replicates exclusively in epithelial cells. In CHO and Cos1 cells, wild-type 
papillomavirus L1 gene is effectively transcribed, but not translated. Introduction of an extra 
copy of Ser-tRNACGA to the CHO or Cos1 (but not the empty vector) enabled the expression 
of L1 protein (Gu et al., 2004). Thus, it seems that TCG is a bias codon in these mammalian 
hosts and thus might be assigned to a NNAA.  
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As the codon bias phenomenon is wide-spread in different organisms, utilization of such 
codons for site-specific incorporation of NNAAs could be applied in many expression host 
cells. The limitation would be the engineering of the orthogonal aaRS/tRNA pair that 
matches the bias codon. The competition from a canonical amino acid for the bias codon 
could be minimized by using auxotrophic host cells, and/or by limiting the canonical amino 
acid concentration in the induction medium. Deletion (or conditional inactivation) of the 
tRNA genes corresponding to the bias codon in the host genome may abolish the 
competition. Recent advances in synthetic biology to generate artificial organisms may 
improve this method dramatically, as it holds promise to express target proteins at high 
level and with different NNAA molecules (see section 2.2.6).  
2.2.4 Stop codon 
Generally, protein translation terminates at one of the three stop codons (encoded by UAG 
(amber), UAA (ochre) and UGA (opal)) by the action of protein release factors (RF). However, 
occasional read-through of a stop codon with an amino acid has been observed to happen 
naturally in a variety of species. The suppression is caused by either mutations in the tRNA 
anticodon or mismatches of the codon-anticodon (Beier & Grimm, 2001). Utilization of stop 
codon suppression represents another way to engineer proteins containing NNAAs, and 
generally involves the introduction of an orthogonal aaRS/tRNA pair. 
A growing number of orthogonal aaRS/tRNA pairs have been developed to introduce 
NNAAs site-specifically at amber codons, as it is the least frequently used stop codon in 
both eukaryotic (23% in humans) and prokaryotic genomes (7% in E. coli) (Liu et al., 2007). 
However, ochre and opal suppressors have been evolved for the introduction of NNAAs as 
well (Köhrer et al., 2004). So far, over 70 NNAAs have been site-specifically incorporated 
into target proteins (Liu & Schultz, 2010). Typically, over 95% NNAA incorporation 
efficiency (defined as occupancy rate of NNAA in the full-length product) at the desired site 
can be obtained, making it one of the most frequently used methods for NNAA 
incorporation.  
The main limitation of this method is protein yield. In general, yields in the range of 1-10 
mg/L have been obtained, but 0.5-0.8 g/L has been reported using optimized fed-batch E. 
coli systems (Cho et al., 2011). One reason for the limited yields is the low overall 
suppression efficiency (defined as the percentage of stop codon read-though), generally in 
the range of 10-40%. The low suppression efficiency also limits the number of integration 
sites for NNAAs in a given gene. As the number of inserted stop codons increases, the 
overall suppression efficiency decreases multiplicatively. Several approaches have been 
tested to increase the overall suppression efficiency.  
One way to increase suppression efficiency is to eliminate the competition from RF. In 
prokaryote organisms, RF1 terminates gene translation at UAA and UAG stop codons, RF2 
at UAA and UGA stop codons, and RF3 facilitates the function of RF1 and RF2 (Nakamura 
et al., 2000). The principle of deleting RF1 in E. coli for amber stop codon reassignment was 
demonstrated by Sakamoto and his colleagues (Mukai et al., 2010). As expected, deletion of 
the prfA gene, which encodes RF1, is lethal to the organism. The prfA- bacteria were rescued 
by 1) mutation of seven essential genes containing amber UAG stop codon to UAA stop 
codon and supplementation of these mutant genes with a bacterial artificial chromosome 
www.intechopen.com
 
Protein Engineering 264 
(BAC) plasmid; 2) introduction of an amber suppressor tRNA such as Gln-tRNA or Tyr-
tRNA. The requirement for an amber suppressor tRNA with a canonical amino acid can be 
extended to amber suppressor tRNA designated for a NNAA. In fact, when an 
archaebacterial TyrRS/tRNACUA pair (engineered for 3-iodo-L-Tyr) was introduced to 
replace the E. coli amber suppressors, 3-iodo-L-Tyr was incorporated to the target protein 
containing six copies of the amber stop codon (Mukai et al., 2010). The target protein 
expression level was not reported, but the full-length protein expression was demonstrated 
by western blot analysis. Such a result is very impressive given that six amber codons were 
read in the target protein, and it was only made possible by eliminating competition from 
the RF-1. However, the introduction of multiple mutated components in an E. coli host strain 
may be problematic for commercial manufacturing. The advent of designer organisms, 
containing artificial genomes, may provide the right solution to address these concerns and 
offer unprecedented potential for NNAA applications.  
Deleting RF is not feasible in yeast and mammalian cells since eukaryotes have a single RF 
that functions for all three stop codons. One can minimize competition from RF by 
increasing the overall abundance of functional tRNA levels. However, the expression of 
most heterologus (usually prokaryotic) tRNA in eukaryotes is problematic due to their 
divergent transcriptional regulation. Eukaryotic tRNAs are transcribed by RNA Polymerase 
III (Pol-III) that is regulated by intragenic promoter regions known as A- and B- box 
elements. Most prokaryotic tRNAs do not contain these consensus sequences and are poorly 
transcribed in eukaryotic cells. Careful selection of a prokaryotic tRNA that contains 
consensus A- and B- box elements, or are permissive to mutation in order to include them, 
has been used successfully (Sakamoto et al., 2002;Zhang et al., 2004). However, the strict 
recognition elements of aaRSs for tRNAs often prevents modifications of the tRNA sequence 
to introduce these elements. Several extragenic promoters for Pol-III have been shown to 
allow for high levels of heterologous tRNA expression in both yeast and mammalian cells.  
In mammalian cells, the promoters for the small nuclear RNA U6 and H1 have been used 
successfully (Mukai et al., 2008). But, RNA expressed by the U6 promoter has been shown to 
mislocalize to nucleoli (reviewed by Haeusler & Engelke, 2006) and may affect the 
processing and targeting of the transcript, both important processes required for the 
generation of functional tRNA. In yeast, RNA Pol-III -based promoters for the tRNA (e.g. 
SUP4), and other RNAs (RPR1 and SNP52), were shown to efficiently express tRNA genes. 
Levels of expression could be increased by coupling these promoters with RNA Pol-II-based 
promoters (e.g. PGK1).  Interestingly, correct processing of the tRNA, and not absolute 
expression levels, is essential to generate functional tRNA and increase NNAA 
incorporation (reviewed by Wang et al., 2009).  
Another limiting factor to incorporate NNAAs at amber codon is a mechanism that 
degrades mRNA containing premature stop codons, called nonsense mediated mRNA 
decay (NMD). Since the most prevalent site-specific integration method includes amber 
codon read-through, the degradation of the target mRNA can have a significant impact on 
the yield. The importance of this process was highlighted when Wang and co-workers 
developed a yeast strain lacking an essential component of the NMD mechanism, UPF1. 
Strains lacking this gene exhibited a two-fold increase in target gene expression when 
compared with wild type cells (Wang & Wang, 2008). A similar approach has not been 
accomplished in higher eukaryotic cells. 
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2.2.5 Four-base-pair codon or non-natural base pair 
The discovery of frame shift suppressor tRNA has opened another door to expand codons 
for NNAAs. In principle, a four-base codon can be used at a desired site in a target gene and 
read by a complementary suppressor tRNA (containing a four-base anticodon), leading to a 
reading frame shift and synthesis of a full length protein. Four-base codons have been used 
to incorporate L-homoglutamine in E. coli, using the orthogonal mutant Pyrococcus horikoshii 
LysRS/tRNAAGGA pair (Anderson et al., 2004). The observed incorporation efficiency is 
similar to those seen for amber codon suppression (>95%) but the overall yields, in the order 
of 1-2 mg/L, are significantly lower. The yield of target protein with NNAA is affected by 
the competition of the host tRNA (containing a triplet codon) for the first 3 bases in the 4-
base codon. As such, competition gives rise to a different reading frame and a protein of 
different sequence. To minimize this competition by the host tRNA, the 4-base codon often 
targets a rare codon (Anderson et al., 2004). When the P. horikoshii LysRS/tRNAAGGA pair 
was co-expressed with an Mj.TyrRS/tRNACUA pair for O-methyl-L-Tyr, target protein 
containing two NNAAs was generated with no appreciable loss in yield or efficiency 
(Anderson et al., 2004). Additional variants of this approach using five-base codons have 
been successfully demonstrated in vitro (reviewed by Hohsaka & Sisido, 2002). Together, the 
use of four- and five-base codons will greatly increase the number determinants for NNAAs 
and provides one method that skirts the limitations of stop codon suppression and allows 
for the introduction of multiple NNAAs into a single protein. However, this approach 
suffers from the relative inefficiency of ribosomes to translate an extended codon. But, one 
can envision the development of modified, orthogonal ribosomes with increased efficiency 
at these codons, as described in section 2.2.7.  
An alternate strategy to encode NNAAs involves the generation of codons made of new 
base pairs. Pioneering work by Benner and colleagues showed that new codon-anticodon 
pairs could be functionally introduced to support translation. By introducing a new letter to 
the genetic lexicon, the number of coding triplets can effectively be increased from 64 to 216. 
Using two complementary base-pairs, termed isoC and isoG to generate a new codon, 
Benner and colleagues introduced p-iodo-Tyr into a short peptide sequence in a cell free 
expression system utilizing chemically synthesized mRNA and tRNA (Bain et al., 1992). But 
to expand the capacity for protein expression this technology requires an expansion into in 
vivo systems. This is a significant hurdle as the new base-pairs need to be orthogonal to the 
existing nucleotides and be accepted by DNA and RNA polymerases for faithful replication 
and transcription. Some of these challenges are beginning to be addressed: Benner and 
colleagues showed that the ribosome could translate a 65th codon (Bain et al., 1992). In 
addition, recent progress in the design of new nucleotide pairs has been made that are 
specific and stable, like 2-amino-6-(2-thienyl)purine and pyridine-2-one, and can be 
faithfully integrated by polymerases into tRNA and mRNA, and be translated in vitro (Hirao 
et al., 2002;Hirao et al., 2004) . By combining these features with an orthogonal aaRS for the 
aminoacylation of tRNA with a synthetic base at its anticodon all the elements for in vivo 
transcription-translation would be in place.  
2.2.6 Reserved codon in artificial cells  
Incorporation of NNAAs into recombinant protein in vivo requires the reassignment of a 
codon (such as a sense codon or a stop codon) to the NNAA, and this inevitably introduces 
competition from the existing endogenous components: the canonical amino acid for the 
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sense codon and protein release factor for the stop codon. Such competition will not only 
reduce the NNAA incorporation efficiency, but may also reduce the target protein 
expression yield. Recent breakthroughs in de novo synthesis and implantation of an entire 
prokaryotic genome to create a living artificial organism (Gibson et al., 2010) provide the 
ultimate solution for the codon competition problem.  
Generation of an artificial synthetic organism via synthetic biology has many applications, 
as the entire genome can be tailor-designed. One such application is for NNAA technology 
by reserving specific codons for NNAAs and by removing the endogenous competition 
components. For example, the host genome may be designed with fewer than the 61 sense 
codons. The tRNA genes might also be minimized, potentially avoiding tRNAs such as 
those with wobble base-pair properties as much as possible. Such design may enable the 
complete reassignment of particular sense codons to a NNAA. To make better use of stop 
codons, host genes might be designed with as few as one type of stop codon so that the 
unused ones may be reserved exclusively to encode the NNAA. This will avoid the toxic 
effect often observed in the existing expression system with stop codon suppression, 
presumably caused by the functional inactivation of essential genes due to NNAA-mediated 
translation extension at stop codons. Furthermore, a release factor (RF) may be eliminated 
from the host genome to avoid premature translation termination of target proteins at the 
stop codon intended for the NNAA. In prokaryotes, the UAA stop codon is recognized by 
both RF1 and RF2, while the other two stop codons are each recognized by a single RF 
(UAG by RF1 and UGA by RF2). RF1 may be deleted from the artificial genome if all host 
genes are terminated with UGA/UAA, reserving UAG for the NNAA; alternatively, RF2 
may be deleted if all artificial host genes are terminated with UAG/UAA, so that UGA is 
reserved for the NNAA. Deletion of RF for eukaryote organisms may need some 
manipulation of the wild-type eRF1, as eukaryote cells have only one eRF1 for all three stop 
codons.  
It should be mentioned that for the majority of current expression systems, the NNAA is 
supplied in the culture media, from where it is transported into host cells and taken up by 
the aaRS. However, some NNAAs may be synthesized in the host cells by manipulating 
metabolic pathway(s). For example, L-homoalanine can be made biosynthetically in large 
quantity when a mutant glutamate dehydrogenase and an exogenous threonine dehydratase 
were introduced to threonine-hyperproducing E. coli (Zhang et al., 2010). By introducing a 
biosynthetic pathway for the p-amino-Phe (pAF) from S. venezuelae into E. coli host (which 
also contains an orthogonal pair of pAF-RS/Tyr-tRNACUA), target protein with p-AF 
incorporated at the amber codon was produced (Mehl et al., 2003). With deep understanding 
of various metabolic pathways, synthetic cells may be designed to integrate NNAA 
biosynthesis with NNAA incorporation, thus substantially reduce the cost of the target 
proteins. 
2.2.7 Orthogonal ribosome 
Incorporation of NNAAs via orthogonal ribosomes was lead by Chin and his colleagues, to 
overcome cell toxicity and low suppression efficiency associated with the amber 
suppression method, and to expand the numbers of NNAAs that can be introduced to target 
proteins. Through screening of a ribosome mutational library, they have identified ribosome 
www.intechopen.com
 
Protein Engineering with Non-Natural Amino Acids 267 
variants that recognize unique ribosome binding sequences (o-RBS). The orthogonal 
ribosome (o-Ribo) functions in parallel with, but independently from endogenous ribosome 
in host cells: o-Ribo does not translate cellular mRNAs, and the target gene cloned with o-
RBS is not translated by the endogenous ribosome (Rackham & Chin, 2005). Subsequent 
evolution identified a mutant Ribo-x (containing U531G and U534A mutation in 16s rRNA) 
that improved the amber tRNA suppression of the target gene (Wang et al., 2007a). By 
combining the Ribo-x, o-RBS-target gene that contains an amber codon, and an orthogonal 
aaRS/tRNA pair for NNAA into E. coli, these investigators were able to significantly 
increase the amber suppression efficiency (from 20% to >60% for a single amber codon, or 
from <1% to >20% for double amber codons) (Wang et al., 2007a). In addition, a ribosome 
variant (Ribo-Q1) that efficiently decodes both quadruplet codons and amber codons was 
evolved (Neumann et al., 2010b). By introducing two mutually orthogonal aaRS/tRNA pairs 
in E. coli host containing Ribo-Q1, they could incorporate two different NNAAs molecules 
into one target protein (Neumann et al., 2010b).  
The protein yield obtained with orthogonal ribosome system is very impressive when 
compared with results obtained with wild-type ribosome. For example, full-length protein 
with two NNAA molecules (assigned to amber codon and a quadruplet codon, respectively) 
was produced at 0.5 mg/L (Neumann et al., 2010b). However, the expression system 
contains multiple components, and its application in large scale manufacturing remains to 
be explored.   
3. Orthogonal chemical reactions at the side chain of non-natural amino 
acids  
One of the major advantages of incorporating NNAAs into proteins is the ability to 
introduce orthogonal, site-specific chemistries for modification of the recombinant protein. 
These modifications are often desired for applications such as PEGylation, drug conjugation, 
or labelling (see section 4). 
Techniques for chemical modification of proteins have steadily increased in their 
sophistication. Early methods used electrophilic addition to the ε-amine groups of lysines. 
However, the large number of reactive lysines in a protein gives rise to a heterogeneous 
reaction product. For instance, PEG-Intron™ contains 15 positional isomers of PEGylation 
sites, in addition to multi-PEGylated species (Wang et al., 2002). The various isomers 
possess 6-37% bioactivity compared to the unPEGylated protein. Conjugation technology 
then shifted to reductive amination at the N-terminus or thiol-specific additions at 
engineered cysteine residues (Harris & Chess, 2003). However, even these approaches do 
not result in complete limitation to a single reaction site, and they also introduce 
significant limitations in conjugation site and/or requirements for more protein 
engineering. 
With the introduction of NNAAs at defined sites in a protein, a whole new world is opened 
up to the conjugation chemist (Sletten & Bertozzi, 2009). A new array of functional groups is 
available and reactions that are orthogonal to (do not react with) the functional groups in 
canonical amino acids present the opportunity for truly site specific conjugations. The 
requirements are that the necessary functional group can be incorporated into the 
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recombinant protein, the complementary functional group can be installed on the other 
molecule to be conjugated, the reaction can occur in conditions acceptable for the protein 
(typically aqueous, 5-37°C, mild pH, preferably in air), the reaction does not cause 
unacceptable side reactions (e.g., metal-catalyzed degradation of amino acids, disulfide 
shuffling of a folded protein), and that the chemistry is suitably bioorthogonal. Useful 
functional groups available in commonly incorporated NNAAs include azides, alkynes, 
alkenes, ketones, and aryl halides (Figure 4). The following sections highlight the most 
frequently harnessed NNAA conjugation chemistries in this rapidly evolving field. 
 
Fig. 4. NNAAs frequently used for bioconjugation. Met analogs: 1 azidohomoalanine (Aha, 
azide group), 2 homopropargylglycine (Hpg, alkyne group), 3 homoallylglycine (Hag, 
alkene group). Phe analogs: 4 p-acetyl-Phe (ketone group), 5 p-azido-Phe (azide group), 6 p-
propargyloxy-Phe (alkyne group). 
3.1 Copper-catalyzed azide-alkyne cycloaddition (“click” chemistry) 
Copper-catalyzed azide-alkyne cycloaddition (often referred to as “click” chemistry or 
CuAAC) was first reported simultaneously by both Sharpless and Meldal and co-workers 
(Rostovtsev et al., 2002;Tornoe et al., 2002). Click chemistry is a term coined by the Sharpless 
group referring to a philosophy of efficient chemical synthesis, but has since been co-opted 
to also refer specifically to CuAAC. CuAAC joins a terminal alkyne and an azide, via a Cu(I) 
catalyst, to form an aromatic triazole ring (Figure 5). Huisgen had previously demonstrated 
catalyst-free cycloaddition of azides and alkynes at high temperature (e.g., 100°C), but with 
the addition of the copper catalyst, the reaction occurs readily at room temperature and 
forms only the 1,4 regioisomer. It is essential that the alkyne is terminal, so the copper 
acetylide can be formed as a reaction intermediate. 
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Fig. 5. Copper-catalyzed azide-alkyne [3+2] cycloaddition (“click” chemistry or CuAAC). 
An azide and a terminal alkyne combine to form an aromatic triazole linkage. 
There are several advantages to CuAAC for bioconjugation. Azides and alkynes do not react 
with canonical amino acids, are kinetically stable, and yet are highly primed to react when 
presented with the appropriate catalyst. Either functional group is readily installed by the 
simple codon reassignment method with commercially available NNAAs. At physiological 
temperatures, the reaction does not occur in the absence of the catalyst.  Importantly, the 
resultant linkage between the protein and the conjugated molecule is a triazole group, 
which is highly stable due to its aromaticity. The reaction can be performed in many 
aqueous buffers at a wide range of pHs, in many organic solvents, in the presence of SDS 
(Grabstein et al., 2010), and, in most cases, in the presence of oxygen. Importantly, the 
reaction displays especially rapid kinetics (Presolski et al., 2010). 
As stated, CuAAC is catalyzed by Cu(I). Cu(I) is not stable in water, but rapidly 
disproportionates into Cu(II) and Cu(0). Cu(I) salts such as CuBr and [Cu(NCCH3)4][PF6] 
have been used successfully, though the literature suggests ultra high purity may be 
required (Link et al., 2004). More frequently, the cupric salt CuSO4 is used in conjunction 
with a reducing agent such as TCEP or elemental copper. Thiol-containing reducing agents 
such as DTT can also be used (Grabstein et al., 2010). Finn and colleagues have recently 
developed the use of aminoguanidine as an additive to prevent deleterious side reactions 
when using sodium ascorbate as a reducing agent (Hong et al., 2009). 
A ligand is typically added to greatly increase reaction yields. The ligand is thought to 
complex and stabilize the Cu(I) and intermediates and also to protect the protein from 
deleterious effects of copper. The most commonly used ligand is TBTA, shown in Figure 6. 
Significant protein breakdown can be seen after reaction with no ligand, whereas 
breakdown can be prevented by TBTA (unpublished data). TBTA is very hydrophobic, but 
solubility is not required for the reaction. Many other ligands have been investigated in the 
literature, including water soluble analogs such as THPTA and benzimidazoles. Finn and 
colleagues have had good success with a water soluble bathophenanthroline ligand ( Gupta 
et al., 2005), but this requires careful removal of oxygen from the system. A thorough 
structure-function investigation of ligand acceleration generated recommendations for 
different systems (Presolski et al., 2010). Dilute reactions in aqueous media have very 
different requirements than concentrated reactions in organic solvents due to the varying 
degree of copper binding competition in the reaction. The literature and the authors’ own 
experience suggests that the best ligand must be determined empirically for any given 
reaction, which will depend on the protein, solvent, and other conditions. 
While CuAAC can be readily employed in many systems, there are some side reactions that 
can be problematic. First, copper is well known to create oxidative species in aqueous 
solution, including hydrogen peroxide and free radicals. These effects can be mediated by 
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choice of ligand, reducing agent, and other reaction conditions. Copper’s toxicity can also be 
problematic for reactions on live cells or in living organisms. Second, the presence of 
reducing agents (or even the copper itself) can disrupt disulfide bonds present in a folded 
protein. This can lead to misfolding or disulfide-linked aggregates, though it has been 
shown that some proteins such as antibodies can be exposed to reducing agents and then 
oxidized to re-form the correct disulfide bonds (Sun et al., 2005). Third, Back and co-workers 
have shown that reducing agents can result in azide reduction to an amine group or can 
cleave the peptide bond C-terminal to Aha, wherein the Aha is modified to a homoserine 
lactone which can then react with amine groups (Back et al., 2005).  High pH can also result 
in direct replacement of the azide group with a hydroxyl group. We have developed 
reaction conditions that avert all of the above issues, apart from toxicity in living systems, 
for various protein conjugation systems (unpublished data). Recent publications have also 
demonstrated conditions that allow short-term CuAAC in the presence of live cells or 
organisms (Hong et al., 2010; del Amo et al., 2010). 
 
Fig. 6. Popular ligands for CuAAC 
3.2 Strain-promoted azide-alkyne cycloaddition 
Strain-promoted azide-alkyne cycloaddition (SPAAC) is popular as a metal-free alternative 
to CuAAC (Jewett & Bertozzi, 2010). While CuAAC uses a copper catalyst to access the 
reactivity of the alkyne, the [3+2] cycloaddition activation barrier can also be lowered by 
placing strain on the alkyne group. Bertozzi and colleagues first pioneered this approach by 
using a highly strained (18 kcal/mol of ring strain) cyclooctyne ring (Agard et al., 2004). As 
shown in Figure 7, the alkyne is internal rather than terminal, the resultant linkage is 
comprised of two fused rings, and no metals, reducing agents, or ligands are necessary. 
SPAAC is of particular interest for labelling applications in living systems in order to avoid 
a toxic copper catalyst. 
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Fig. 7. Strain-promoted azide-alkyne [3+2] cycloaddition (SPAAC). An azide and a strained 
cyclooctyne ring combine to form a fused ring linkage. 
SPAAC has undergone significant improvements beyond the slow reactivity and difficult 
synthesis of the original cyclooctyne ring. Installation of electron withdrawing groups on 
the cyclooctyne or additional ring strain provided by fusing ring(s) to the cyclooctyne has 
improved reaction kinetics, and a practical focus has improved synthetic accessibility of the 
starting materials. A sampling of structures is given in Figure 8. An initial advance occurred 
with DIFO, where the introduction of two propargylic fluorine atoms resulted in more than 
an order of magnitude increase in the second-order rate constant. Second generation DIFO 
analogs displayed similar reactivity but synthetic yields were improved from 1% in 12 steps 
to 28-36% in 6 steps. Increasing ring strain by fusing two aromatic rings with the 
cyclooctyne has also increased reactivity to similar levels, such as with DIBO. Addition of a 
nitrogen atom (DIBAC) or amide group (BARAC) within the central cyclooctyne ring 
increases the reactivity even further (Debets et al., 2010;Jewett et al., 2010). Alternatively, ring 
strain introduced by fusion of a 3-membered ring with the cyclooctyne generates a 
bicyclononyne (BCN) with similarly high reactivity (Dommerholt et al., 2010). This molecule 
was made in 4 steps with an overall synthetic yield of 46% and, due to its symmetry, its 
cycloaddition reaction product is a single regioisomer. These improved reagents have now 
brought SPAAC reactivity to a similar level as CuAAC. A much more water soluble reagent 
was generated by the addition of 3 heteroatoms to the single cyclooctyne ring (DIMAC), but 
the reactivity was significantly lower than other recent analogs. 
 
Fig. 8. Improved strained alkynes for use in SPAAC. 
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SPAAC can expand the application of azide-alkyne cycloaddition to metal-sensitive 
systems, but it does present some challenges. Unfortunately, many of the modifications that 
reduce the activation barrier enough for fast reaction rates also reduce the barrier for side 
reactions with canonical functional groups such as cysteinyl thiols.  This loss of 
orthogonality can be addressed by tailoring of the activated alkyne and reaction conditions, 
but ultimately the stringency of the orthogonality requirement is dependent upon the 
application. In addition, the cyclooctyne ring is a large hydrophobic structure with limited 
aqueous solubility. It has been shown to nonspecifically bind to proteins even in the 
presence of SDS (Sletten and Bertozzi, 2008). The fusion of additional rings only serves to 
magnify this problem (Agard et al., 2006;Codelli et al., 2008). Commercial availability of 
cyclooctyne reagents is also limited. For applications such as therapeutic protein conjugates, 
other considerations include the stability of the activated alkyne, its synthetic availability 
and purity, and the production of regioisomers in the reaction product. Importantly, the 
final fused ring linker that is generated is bulky, rigid, hydrophobic, and still contains some 
strain. Whether this presents any challenges for immunogenicity or stability of a therapeutic 
conjugate remains to be investigated. 
3.3 Carbonyl chemistries 
Carbonyl chemistries for creating oxime or hydrazone linkages are well established methods 
for protein conjugation. With this approach, a ketone or aldehyde handle is reacted with an 
aminooxy or hydrazide group to form an oxime or hydrazone linkage (Figure 9). The reaction 
is extremely selective with the exception that N-terminal cysteines will undergo thiazolidine 
formation. The reaction is typically performed around pH 4-5 to facilitate protonation of the 
carbonyl but maintain the nucleophilicity of the aminooxy group.  No metal catalysts are 
required and the final linker is a small inconspicuous group. The recent discovery of aniline as 
a nucleophilic catalyst of this reaction was key to extending the utility of this reaction, even 
making conjugation at neutral pH viable (Dirksen & Dawson, 2008). 
 
Fig. 9. Carbonyl chemistries, X = H for aldehydes, X = R for ketones. (A) A carbonyl and an 
aminooxy group combine to form an oxime linkage. (B) A carbonyl and a hydrazide group 
combine to form a hydrazone linkage. 
The final oxime and hydrazone linkages can degrade, undergoing hydrolysis to regenerate 
the starting materials (Kalia & Raines, 2008). Hydrazone half lives can be on the order of 
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minutes to hours, so oximes are the linkage of choice for stable bioconjugates. The half life of 
a simple oxime was reported as ~25 day at pD 7.0 but dropped to 15.7h at pD 5.0 due to the 
acid catalysis of this degradation. The chemistry of neighboring groups (electron 
withdrawing or donating, aromaticity) can be tailored for desired stability. Importantly, 
researchers at Ambrx have recently reported stability for more than 1 year at pH 7.3 of a 
PEGylated growth hormone containing an oxime linkage through p-acetyl-Phe (Cho et al., 
2011). On the other hand, the instability of the hydrazone can be used as a tool, such as for 
temporary labelling or purification purposes. The ability of the final linkage to hydrolyze 
can also be a potential advantage if a therapeutic conjugate is desired to eventually degrade 
in vivo. Another problem when working with proteins containing carbonyl groups is 
reversible imine formation between the carbonyl group and lysinyl amino groups. 
While the optimal reaction pH of 4-5 is not extreme, it is not desirable for some proteins, 
especially if this is near the pI. The reaction is often performed at a suboptimal pH in order 
to keep the protein in solution. When hGH (pI ~5) was PEGylated by oxime chemistry, 15% 
DMF was added and the reaction was performed at pH 6 to prevent precipitation, 
necessitating an amazing 10 days at 30°C for the reaction (Peschke et al., 2007). When the 
same investigators utilized CuAAC, the reaction took place over 22h with a much higher 
final yield of protein. The final conjugate also had a higher in vitro potency after CuAAC, 
perhaps due to the suboptimal conditions the protein was exposed to for the oxime 
conjugation. 
3.4 Staudinger ligation 
Bertozzi and colleagues have pioneered the Staudinger ligation as another orthogonal 
conjugation chemistry reactive to azide-containing NNAAs (Saxon & Bertozzi, 2000). In this 
reaction, a triarylphosphine moiety forms an aza-ylide intermediate (iminophosphorane) 
with the NNAA (Figure 10). A methyl ester group ortho to the phosphorous atom provides 
an electrophilic trap for the nitrogen, causing rearrangement to the final amide linkage. 
Raines and colleagues have since developed a traceless Staudinger ligation (Figure 10), 
wherein a phosphinothioester reacts with the azide to form an aza-ylide, which undergoes a 
rearrangement to form an amide bond with release of the phosphine oxide (Tam & Raines, 
2009). Thus, no “trace” of the phosphine group remains in the conjugated product. Various 
water soluble phosphinothiols are now available, incorporating amine groups that also 
favor the ligation over hydrolysis. 
The Staudinger ligation has benefits including the lack of a metal catalyst. No ligation occurs 
with canonical amino acids and the reaction has been shown to work even on crude cell 
lysates. Particularly appealing in the case of the traceless ligation is that a simple amide 
bond is the reaction product. 
Challenges with the Staudinger ligation include competing side reactions and the nature of 
the phosphine reagent. The design of the phosphine group is important to drive ligation 
rather than the competing classical Staudinger reaction. In the classical reaction, hydrolysis 
of the aza-ylide results in reduction of the azide to an amine and release of the phosphine 
oxide. The ligation works best around pH 8, presumably due to higher hydrolysis 
competition at acidic pH. Phosphines are also known to reduce disulfide bonds. Fortunately, 
triarylphosphines are mild reducing agents, and were shown not to induce significant 
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disulfide reduction on a cell surface (Saxon & Bertozzi, 2000). Aryl phosphines are, however, 
very bulky (affecting reaction rates on protein surfaces), hydrophobic (affecting solubility of 
the reagent), and still prone to oxidation by air (requiring special handling). In the case of 
the nontraceless ligation, the aryl phosphine leaves a bulky hydrophobic signature in the 
linkage. 
 
Fig. 10. (A) Staudinger ligation – an azide and a triarylphosphine moiety bearing an 
electrophilic trap combine to form an amide linkage bearing the triarylphosphine oxide. (B) 
Traceless Staudinger ligation – an azide and a phosphinothioester combine to form an 
amide linkage. (C) Classical Staudinger reaction – an azide reacts with a phosphine to form 
an amine and a phosphine oxide. 
Reaction kinetics are perhaps the most significant shortcoming of the Staudinger ligation. 
The rate is orders of magnitude slower than other available chemistries. Attempts to 
accelerate the reaction by increasing the electron density of the phosphine substituent also 
increased the air instability of the reagent. The slow reaction rates, combined with air 
instability and competing hydrolysis, may be why the Staudinger ligation is used less 
frequently than other conjugation chemistries. 
+
N3
O
Ph2P
H3CO
O
PPh2
H3CO
N
O
P
Ph2
N
O
PPh2
NH
O
-N2
-CH3O
H2O
A
B
N3
S
O
Ph2P S
O
Ph2P
N
S
Ph2P
N
O
N
O
PPh2
S
N
H
O
-N2
H2O
+
N3 -N2
+ PR3
N PR3 H2O NH2
+ PR3O
C
HS PPh2
O
+
www.intechopen.com
 
Protein Engineering with Non-Natural Amino Acids 275 
3.5 Other reactions 
Due to the abundant applications, new chemistries are constantly in development for site 
specification conjugation to proteins containing NNAAs. Summarized below are a number 
of interesting approaches, some of which await further refinement before implementation as 
a readily available bioorthogonal strategy. 
3.5.1 Metal-free 
A tandem 1,3-dipolar cycloaddition-retro-Diels-Alder (tandem crDA) has recently emerged 
as an intriguing metal-free alternative to CuAAC (van Berkel et al., 2008). In this reaction, an 
azide group is reacted with a strained and electron deficient oxanorbornadiene derivative. 
The azide undergoes [3+2] cycloaddition with one of the double bonds, which is followed 
by elimination of a furan in a retro-Diels-Alder reaction, leading to formation of a stable 
1,2,3-triazole. While an elegant approach, the reaction can take days to complete and side 
reactions with basic canonical amino acids can occur. Most importantly, the addition can 
also take place over the unsubstituted double bond in the strained ring; this results in 
elimination of the desired substituent and the conjugate is not formed. Hopefully further 
refinements will enable this chemistry for more general use. 
Cycloadditions between alkenes and tetrazines or tetrazoles have also been an active area of 
research for bioorthogonal conjugation. In the inverse electron demand Diels-Alder 
cycloaddition, a strained alkene dienophile undergoes cycloaddition with a tetrazine, 
leading to a fused ring conjugate and elimination of N2 (Blackman et al., 2008;Devaraj et al., 
2008). The reaction is fast, selective, and metal-free. However, the reaction requires an 
alkene (such as trans-cyclooctene or norbornene) with much more strain than NNAAs that 
have been incorporated in vivo (such as homoallylglycine). One solution has been to use a 
tetrazole that can be photoactivated to produce a nitrile imine intermediate that then reacts 
with unactivated alkenes (Song et al., 2008). This has been used successfully with a Z-
domain protein containing O-allyl-Tyr expressed from E. coli. 
The cycloadditions of strained alkynes or alkenes with nitrile oxide have also been 
investigated recently (Gutsmiedl et al., 2009). The reaction also occurred with an unstrained 
alkyne and in situ formation of the nitrile oxide by hypervalent iodine, but was sluggish 
(Jawalekar et al., 2011). This approach suffers from a lack of incorporatable NNAAs 
containing the ideal functional groups and also the nitrile oxide can undergo side reactions 
with other functional groups or homodimerize with itself. 
As an alternative to SPAAC, appendage of electron-withdrawing groups neighboring an 
alkyne can also enable azide-alkyne cycloaddition without a metal catalyst (Li et al., 2004). 
Similarly to SPAAC, refinement of the local environment of the alkyne is necessary to 
promote a desirable reaction rate while maintaining orthogonality, but this approach avoids 
the use of bulky rings in the reactants. 
Various photoactivated chemistries have been used, either with photoreactive NNAAs or by 
generation of reactive functional groups through irradiation. However, photoirradiation is 
well known to generate other reactive species such as free radicals that could cause side 
reactions with proteins and can also be difficult to scale up for a manufacturing process, and 
thus is not discussed in depth in this practical review. 
www.intechopen.com
 
Protein Engineering 276 
Thiol-ene coupling to form a thioether linkage between thiols and alkenes has also gained 
recent popularity (Dondoni, 2008). Photoirradiation or free radical initiators are used to 
generate a reactive thiyl radical. This approach has been recently used to generate various 
bovine serum albumin conjugates. A similar thiol-yne coupling with alkynes can also be 
utilized (Minozzi et al., 2011). For the application of thiol-ene/yne chemistry to NNAA-
containing proteins, it would be possible to incorporate an alkene- or alkyne- containing 
NNAA and conjugate it to a thiol-containing substituent. However, given the prevalence 
and importance of cysteine residues in most proteins, and the side reactions to be expected 
by deliberate free radical generation, the generalizability of this approach for bioorthogonal 
reactions with NNAA-containing proteins is limited. 
3.5.2 Metal-catalyzed 
The family of palladium-catalyzed cross coupling reactions has great potential for 
bioorthogonal conjugations. These include couplings between an aryl or vinyl halide and an 
alkyne (Sonogashira), alkene (Heck), or boronic acid (Suzuki) group (Genet & Savignac, 
1999). The Sonogashira coupling typically also includes a Cu(I) cocatalyst. The simple 
carbon-carbon linkage that is formed is very appealing with respect to stability and bulk. 
Classically these reactions are performed in organic solvent, under inert atmosphere, and 
with significant heat. However, recent advances in this rapidly evolving area have enabled 
these reactions for mild aqueous conditions.  
These palladium-catalyzed reactions have now been employed for protein modification 
with varying success. Ras protein containing 4-iodo-Phe has been conjugated, via Heck or 
Sonogashira couplings, with vinylated or propargylated biotin (Kodama et al., 2007). The 
reactions yielded only 2 - 25% product and the addition of DMSO, MgCl2, and tyramine was 
required to reduce protein degradation and to suppress cysteine interference. More success 
has been seen with Suzuki couplings, performed with up to quantitative yields with 4-iodo-
Phe-containing proteins (Ojida et al., 2005;Chalker et al., 2009). Issues with protein 
precipitation, dehalogenation, and cysteine interference could still be seen. Less success was 
seen when coupling a boronic acid-containing protein by Suzuki coupling (Brustad et al., 
2008). An important limitation to all Pd-catalyzed reactions is that the catalyst is easily 
poisoned by thiols and the presence of free cysteines (and potentially even cystines or 
methionines) can often block the reaction completely.  
Ruthenium has emerged as a different metal that can catalyze the cycloaddition of azides 
and alkynes (Zhang et al., 2005). Unlike CuAAC, the reaction is catalyzed by the metal in the 
+2 oxidation state and internal or terminal alkynes can be used. Also, depending on the 
catalyst complex used, the reaction product can be the 1,4- or the 1,5- disubstituted 
regioisomer of the triazole. One potential side reaction is oligomerization of the alkyne. 
RuAAC has been used to ligate pancreatic ribonuclease with a cis-peptide bond surrogate 
(Tam et al., 2007). 
Olefin cross-metathesis, the exchange of fragments between double-bond-containing 
molecules, has recently been applied to protein conjugations (Lin et al., 2009). This has been 
enabled by the development of ruthenium-based catalysts that are air stable and active in 
water. Davis and co-workers recently demonstrated the first cross-metathesis coupling 
reactions with a protein (Lin et al., 2010). A protein containing S-allylcysteine reacted 
quantitatively with alkene-containing glycosides after short times at 25-37°C. The reactions, 
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however, took place in 30% tert-butyl alcohol and required addition of MgCl2 as a mild 
Lewis acid to prevent non-productive chelation. The proximity of the sulfur seems to be 
critical for rate enhancement. Unfortunately, homoallylglycine, which can be readily 
incorporated into proteins, is much less reactive. Olefin metathesis is attractive due to the 
simple alkene bond that is formed between the substituents. Potential issues with olefin 
cross metathesis include self-metathesis homodimerization side reactions and interference 
from sulfur atoms (cysteine, cystine, methionine). 
4. Potential applications of proteins engineered with non-natural amino acids 
Protein engineering with NNAAs harnesses the vast divergent array of new protein 
building blocks and brings forth many new applications, such as monitoring protein 
functions in vivo via probe-labelling, trapping transient protein-protein interactions via 
cross-linking, facilitating structural determination and proteomic studies for newly 
synthesized proteins. In addition, it may also find practical applications in protein 
purification, materials science, diagnostics, drug screening, and green energy. In this section, 
we will highlight its applications on protein therapeutics and protein functional evolution. 
4.1 Protein therapeutics 
Protein therapeutics represent a $72 billion market with more than 130 products approved 
(Leader et al., 2008). The ability of complex proteins to exquisitely target disease pathways 
continues to drive rapid development despite their high cost of goods. While the proteins 
themselves can offer a strong therapeutic effect, additional modifications such as polymer or 
drug conjugation can improve or add new pharmacodynamic effects. A number of 
conjugated biotherapeutics are already approved for clinical use, including PEGylated 
proteins, antibody-drug conjugates, and saccharide-protein conjugate vaccines. 
First generation conjugate therapeutics suffer from a lack of control over the conjugation site 
and current research is focused on enabling precise direction to a chosen site of 
modification. The expression of proteins with NNAAs at predetermined locations lends 
itself readily to these applications. While many relevant NNAA bioconjugations have been 
reported in the literature, a number of issues must be addressed when considering 
translation to a clinical product. The conjugation reaction must use conditions that are 
amenable to scale-up, use reagents that can be obtained with sufficient purity and scale, 
have cost effective reactant ratios with high yields, and avoid side reactions that can be 
problematic at even very low levels. In addition, the nature of the linkage that is formed 
between the protein and the conjugated species is important with respect to shelf life and in 
vivo stability as well as to immunogenicity of the product. 
In the following sections we provide an overview of NNAA conjugate therapeutic approaches 
that are readily contemplated or have already been reduced to practice. We also provide an 
example of therapeutic effect derived from incorporation of an unmodified NNAA. 
4.1.1 Modifications for improved pharmacokinetics 
Increasing the residence time of protein therapeutics in the body has been a focus of 
biotherapeutic development for some time. Because these pharmaceuticals are typically 
administered by injection, decreasing the dosing frequency from daily to weekly or monthly 
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is highly desirable. This increases patient comfort and compliance, and the maintenance of a 
more steady plasma concentration of the drug, rather than frequent peaks and troughs, can 
increase the therapeutic effect (Harris & Chess, 2003). 
Conjugation of polyethylene glycol (PEG) is the current gold standard for protein half-life 
extension (Fishburn, 2008). There are now at least eight approved PEGylated protein 
therapeutics in the US. PEGylation of proteins is known to decrease renal clearance, 
decrease enzymatic degradation, reduce immunogenicity of the protein, and increase serum 
half-life due to the steric hindrance of a PEG “cloud” around the protein. Upon PEGylation, 
the half-life of a protein may increase by a few-fold to even a thousand-fold. Consequently, 
even though PEGylation typically results in decreased in vitro activity, in vivo efficacy is 
usually greatly enhanced. Alternative polymers for conjugation are under investigation, 
including hydroxyethyl starch. 
The site of conjugation to a protein has important implications. PEGylation near a binding 
or catalytic site of the protein can strongly reduce binding affinity and in vitro potency. As 
discussed in sections 3 and 4.1.3, protein PEGylation can occur through reactive groups such 
as lysinyl amines or cysteinyl thiols, but this provides poor control over the site of and 
number of modification(s). Even reductive amination, which is designed to be selective for 
the N-terminal amine due to its lower pKa, still results in PEGylation at additional sites on 
the protein (Gronke et al., 2010). While multi-PEGylated species can often be purified from 
mono-PEGylated species, separation of positional PEG isomers (monoPEGylation at 
different sites on the protein) is unfeasible in commercial production. The resultant 
heterogeneous product contains isomeric molecules with a range of potencies and provides 
a challenge for batch-to-batch reproducibility. Thus, the field is rapidly moving toward true 
site specific modification to allow production of a single designed homogenous product. 
PEGylation has now been performed through NNAA conjugation, and a few companies are 
advancing these products in the clinic. Allozyne has reported a PEGylated interferon beta-
1b (IFN) produced by incorporating a single Aha as a reassigned sense codon for Met in E. 
coli and then attaching a PEG-alkyne via CuAAC (Nairn et al., 2007). We have since 
produced a PEG-IFN candidate under cGMP at >800L fermentation scale (unpublished 
data). Up to 98% conjugation of Aha-containing IFN was achieved using a low molar 
excess of reactive 40 kDa branched PEG. No PEGylation was seen at any site besides the 
Aha and residual copper in the final product was <0.1 ppm with no special efforts for 
removal. After 18 months storage at 5°C, there was no detected unPEGylated IFN in the 
Drug Product, indicating a very stable linkage. Phase Ia trials showed the resultant half-life 
extension may allow monthly dosing, whereas the unPEGylated analog Betaseron® is dosed 
every other day. Ambrx recently reported clinical data of a PEGylated human growth 
hormone that supports weekly dosing. This molecule was made by amber suppression in E. 
coli with incorporation of p-acetyl-Phe at position 35 followed by reaction with linear 30 kDa 
aminooxy-PEG to create an oxime linker (Cho et al., 2011). As has been seen for other 
PEGylated proteins, variations in the PEGylation site had a significant effect on binding 
affinity and in vitro bioactivity; a systematic comparison in vitro and in vivo was performed 
in order to select the site taken into the clinic. Fermentation was performed at >1000L scale 
with 0.5-0.8g/L titers and the linkage was shown to be stable for more than a year at 5°C. 
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4.1.2 Bispecific protein conjugates 
Bispecific and multivalent proteins are receiving growing interest as therapeutic candidates 
(Marvin & Zhu, 2005;Filpula, 2007). Antibody-like molecules with specificity for two 
different epitopes show promise for targeted cancer therapy, such as by bringing cancer 
cells and effector cells into close contact. Combination of two antibody binding domains also 
has potential for immunotherapy, such as by simultaneously binding two cytokines or to 
regulate multiple pathways by simultaneously binding cell surface receptors. Other 
applications include toxin conjugates, where a proteinaceous toxin is linked to a targeting 
protein such as an antibody binding domain or a targeting ligand. As another approach, 
multivalency of the same protein can improve avidity, targeting, and function.  
Bispecific or multivalent proteins are typically constructed by expression of genetic fusions 
or by conjugation through an engineered cysteine residue. Limitations of genetic fusions can 
include mis-folding, mis-pairing of antibody chains, low fermentation yields, and a lack of 
choices for relative orientation between the proteins, as the linkage can only occur between 
the N-terminus of one protein and the C-terminus of the other (Griffiths et al., 2004;Marvin 
& Zhu, 2005). Engineered cysteine residues can result in mis-disulfide bond formation (Kim 
et al., 2008) and a complex reaction product (Natarajan et al., 2005). 
The use of NNAAs for protein-protein coupling enables production of a single conjugate 
with any desired orientation. It requires that the two target proteins be produced in separate 
fermentations with 2 complementary NNAAs. This can allow independent folding of the 
two proteins prior to conjugation if desired to avoid mis-folding events. 
There are a few examples of protein-protein conjugation through incorporated NNAAs. 
DHFR and GFP (or 2 GFPs) have been directly conjugated through CuAAC between 
incorporated p-propargyloxy-Phe and p-azido-Phe residues (Bundy & Swartz, 2010). Up to 
62% conjugation yield was achieved with a 1:1 molar reactant ratio. Not surprisingly, use of 
a ligand to protect the protein from the copper and removal of the copper prior to assay 
were important to demonstrate that bioactivity was retained. An scFv and a luciferase 
reporter protein have also been conjugated by CuAAC between incorporated Hpg and p-
azido-Phe residues (Patel et al., 2009). Another interesting approach was to react p-acetyl-
Phe genetically incorporated in an anti-HER2 Fab domain with hydroxylamine biotin to 
form an oxime linkage (Hutchins et al., 2011). This conjugate was then assembled into a 
tetravalent species through incubation with deglycosylated avidin. By incorporating the 
NNAA at various sites, the authors showed that the orientation of the protein assemblage is 
important, with 5-50 fold increased in phosphorylation inhibition versus the monovalent 
parent Fab depending on the conjugation site. 
4.1.3 Antibody-drug conjugates and radioimmunoconjugates 
The chemical conjugation of highly potent cytotoxic drugs to monoclonal antibodies has 
proven to be effective means of targeted delivery of chemotherapeutics that would 
otherwise be too toxic for systemic administration (Alley et al., 2010). The key attributes of 
antibody-drug conjugates (ADCs) include the specificity of the antibody for the tumor, the 
potency of the toxin, and the linker, which must release the toxin conditionally upon 
internalization into the tumor cell. ADCs are typically linked via acylation of lysines, 
alkylation of reduced interchain disulfides, or alkylation of introduced unpaired Cys 
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residues. Each of these methods leads to some degree of heterogeneity of the product. 
Modification at native Cys residues produces a mixture of molecules including 0, 2, 4, 6, and 
8 drugs, where the final conjugate also contains less stabilizing disulfide bonds than the 
parent (Sun et al., 2005). The therapeutic index will be highest for a molecule with the ideal 
number of drugs attached, for example, the maximum tolerated dose and clearance rate 
improved by 4-5 fold when comparing ADCs containing exactly 2 auristatin analogs versus 
8 (Hamblett et al., 2004). One approach to limit product heterogeneity is to replace some of 
the natural cysteines with serines (McDonagh et al., 2006). Engineering in new Cys residues 
has also allowed more control over the degree of conjugation, but the reaction product still 
carries a distribution of species (Junutula et al., 2008). 
The ability to introduce a NNAA at any location in an antibody (or Fab, scFv, etc.) provides 
several advantages for ADC construction. The NNAA creates specific sites where the toxin 
is conjugated, leaving all other residues and the disulfide bonds unmodified. These sites can 
be positioned at favorable locations that are permissive for full function of the antibody. The 
number of toxins per antibody can also be efficiently adjusted without sacrificing the yield 
or homogeneity of the product. There are, to our knowledge, no literature reports of ADC 
construction with genetically incorporated NNAAs, but Allozyne and Ambrx are both 
pursuing undisclosed ADC targets for oncology. 
Radioimmunoconjugates for radioimmunotherapy (RIT) are similar to ADCs, but a 
chelating agent for a radionuclide is conjugated instead of a toxin (Martin et al., 2010). The 
design principles are similar to ADCs, where the use of NNAAs to control the location and 
number of attached chelating agents can be expected to substantially improve the product. 
One significant advantage of RIT is that internalization is not required. Thus, there are a 
greater number of available targets. In addition, smaller targeting proteins, such as scFvs 
may be used, which should provide for better tumor penetration. 
4.1.4 Cancer vaccines 
Cancer vaccines hold great promise to treat metastatic tumors effectively and to elicit long-
term protection against recurrence (Farkas & Finn, 2010). However, because most tumors 
are derived from normal cells, the identification of true tumor specific antigens (absent in all 
normal tissues) is difficult. Instead, many tumor associated antigens, especially those self-
proteins over-expressed in tumor, have been identified and used for immunotherapy. While 
it has been shown that cancer vaccines can be effective, it is still a challenge to elicit effective 
immunity against the over-expressed tumor associated antigens because of self-tolerance. 
Introduction of NNAAs into tumor antigens offers potential strategies to break such self-
tolerance, since the NNAA may be recognized as a foreign entity by the immune system. 
Such a theory is supported by animal data (Grunewald et al., 2009): when the wild-type 
murine tumor necrosis factor- was used as an immunogen, mice failed to generate IgG 
antibodies; however, when the mutant protein containing only one NNAA (p-nitro-Phe) was 
used, sustained polyclonal IgG antibodies against both the wild-type as well as NNAA-
containing protein antigens were generated. The resulting immune response protected mice 
from severe endotoxemia induced by lipopolysaccharide (LPS) challenge. Therefore, 
vaccination with NNAA-modified self-protein can break self-tolerance due to epitope 
spreading, resulting in polyclonal antibodies against the native protein.   
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Incorporation of NNAAs into antigens may also improve vaccine efficacy by increasing the 
antigen stability in vivo. This may be of special importance to peptide-based vaccines due to 
the short half-life of peptides. Peptides designed with NNAAs may adopt bioactive 
conformation with enhanced stability, and thus elicit immune response to wild-type tumor 
antigens (Vichier-Guerre et al., 2004;Corzana et al., 2011). 
4.2 Functional evolution of proteins with NNAAs 
Engineering proteins for desired biophysical properties, enhanced or novel functions is of 
central importance, not only for basic scientific research, but also for biopharmaceutical 
drug development. The availability of the vast number of NNAAs as building blocks greatly 
expands our ability to customize proteins for different purposes. Several strategies for 
functional evolution of proteins with NAA are described below. 
Rational-design (based on the known structural information of target proteins) is an efficient 
way to evolve proteins with NNAAs. For example, based on the hyper-hydrophobic and 
near isosteric properties of fluorinated amino acids to their natural counterparts, 
trifluoroleucine (Tfl) introduced to leucine zipper peptides (replacing all Leu residues) has 
been shown to increase the stability while maintaining their DNA-binding function (Tang et 
al., 2001). Molecular dynamics simulation of the thermodynamic properties of the 
fluorinated leucine zipper peptide indicated that Tfl-substituted structure is indeed more 
stable than the wild-type, correlating well with experimental data (Tang et al., 2001). 
Another impressive example involves replacing a single amino acid (Tyr 309) in the bacterial 
enzyme phosphotriesterase with NNAAs (L-(7-hydroxycoumarin-4-yl)ethylglycine and L-
(7-methycoumarin-4-yl)ethylglycine amino acid) (Ugwumba et al., 2011). This enzyme 
catalyzes the hydrolysis of the pesticide paraoxon with very fast turnover rate, which was 
thought to be near the evolutionary limit. However, through a single, rationally designed 
mutation with NNAA, which increased the electrostatic repulsion of the negatively charged 
hydrolysis product, and thus improved the rate-limiting product release step, about a 10-
fold improvement of this already highly efficient enzyme was achieved. Such result is in 
great contrast to the difficulty in improving this enzyme’s activity through screening large 
mutation library with canonical amino acids.   
In the absence of structural information required for rational design, library screening 
methods can be utilized to evolve NNAA-containing proteins for the desired properties or 
functions. Briefly, a target gene containing various mutations is expressed in the presence of 
the NNAA, and the resultant NNAA-containing protein variants are screened and selected 
for the desired properties. While the designs of library (ranging from total random mutation 
library, to the limited mutation library at a few codons), the methods to introduce NNAAs 
into proteins (as reviewed in previous sections), as well as the library screening strategies 
can vary from case to case, the basic principle for functional evolution of proteins with 
NNAAs can be applied broadly for protein engineering. For example, sense codon global 
substitution with a NNAA can often result in the loss of a protein’s structure and function. 
By screening random libraries with a sense codon global substitution method to replace Leu 
with Tfl, a mutant Tfl-containing enzyme with enhanced thermal stability (Montclare & 
Tirrell, 2006) and a mutant Tfl-containing GFP with increased fluorescence intensity (Yoo et 
al., 2007) were obtained. By screening a phage-display scFv antibody library, where six 
residues in the VH CDR3 were randomized, one scFv containing sulfotyrosine was obtained 
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that binds gp120 more effectively than any similarly evolved scFv molecules containing only 
canonical amino acids (Liu et al., 2008). By screening a peptide library based on cellular 
viability, cyclic peptide (containing NNAA) protease inhibitors were derived (Young et al., 
2011). Other NNAA-containing proteins, such as boron-containing proteins for 
carbohydrate binding (Liu et al., 2009), have been evolved as well. Therefore, functional 
evolution of proteins with NNAAs can offer a selective advantage beyond the traditional 
directed evolution with only the canonical amino acids.    
5. Conclusion 
NNAAs greatly expand the amino acid repertoire for protein engineering. The ability to 
introduce NNAAs into proteins is a very important technical advance in the fields of both 
discovery research as well as commercial production of medicines and industrial enzymes. 
There are several established methods to accomplish the incorporation of NNAAs. In most 
cases, the NNAA serves as a point of protein modification. For biopharmaceutical 
applications, the ability to introduce the NNAA at a specific position becomes a very 
important advantage, as protein function is very sensitive to the position of conjugation. 
These new technologies are currently being used in the development of new and better 
protein therapeutics that may soon be on the market. The future will likely include a host of 
new medicines based on this technology, and its many diverse applications.  
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